查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786967

良性前列腺肥大症外科治疗的外科治疗市场规模，占有率，产业分析报告:各类型，各终端用户，各地区-2025～2034年市场预测

Benign Prostatic Hyperplasia Surgical Treatment Market Size, Share, & Industry Analysis Report By Type [Transurethral Resection of Prostate (TURP), Prostatic Urethral Lift], By End User, By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，BPH 外科治疗市场规模预计到 2034 年将达到 34.1257 亿美元。本研究报告深入分析了当前的市场动态，并分析了未来的市场成长。

良性摄护腺增生 (BPH) 外科治疗是指旨在缓解 BPH 引起的泌尿问题的医疗干预措施，通常是在药物治疗无法充分缓解症状时采用。目前，微创手术正日益成为主流，其可加快患者恢復速度并减少术后併发症。随着患者和医疗保健提供者越来越青睐微创治疗方案，扩大采用能够在有效控制症状的同时最大程度减少组织损伤的手术方案。这一趋势反映了以患者为中心的医疗理念的广泛发展，也与全球对手术疗效和改善整体生活品质的关注相一致。

先进外科技术在整个医疗保健体系中的整合也推动着成长机会。雷射治疗、手术机器人和改进的可视化工具等技术创新正在提高良性前列腺增生 (BPH) 手术的精确度和效率。这些进步简化了手术工作流程，使泌尿科医师能够更一致、更安全地执行复杂的手术。因此，医疗保健提供者能够提供个人化护理，从而加速向技术先进、以结果为导向的护理模式的转型。

良性前列腺增生 (BPH) 外科治疗市场报告重点

按类型划分，到 2024 年，经尿道前列腺切除术 (TURP) 将以 7.1343 亿美元的市场规模领先，展现其经过验证的临床有效性，并确立其作为 BPH 治疗的标准。

按最终用户划分，预测期内门诊手术中心 (ASC) 细分市场的复合年增长率预计将达到 5.7%，这得益于对门诊手术和经济高效的医疗服务需求的不断增长。

北美良性前列腺增生 (BPH) 手术治疗市场将占据最大收益占有率，到 2024 年将达到 8.8888 亿美元，这得益于 BPH 的高发病率、先进手术技术的快速普及以及巨额的医疗保健支出。

受泌尿科护理意识的不断增强以及医疗基础设施投资的不断扩大的推动，亚太地区将在 2024 年占据 21.61% 的市场占有率。

全球良性前列腺增生治疗市场的主要参与者包括美国Polyfilm公司、巴斯夫、科思创股份公司、Novotex Italiana S.p.A.、RTP公司和三方化学股份有限公司。

目录

第1章 良性前列腺肥大症外科治疗市场范围更新的根据

第2章 全球良性前列腺肥大症外科治疗市场报告概要

  • 调查范围
  • 市场区隔分析
  • 各地区/国家的法规情势
  • 市场投资情势策略
  • 各类型市场分析
    • 各类型(2024～2034年)
    • 经尿道前列腺切除术(TURP)
    • 前列腺尿道提升术
    • 水蒸气疗法
    • 雷射疗法
    • 水消融疗法
    • 尿道热疗法(TUMT)
    • 其他
  • 各终端用户市场分析
    • 各终端用户的全球良性前列腺肥大症外科治疗市场(2024～2034年)
    • 医院
    • 门诊病人手术中心
    • 诊所
    • 居家照护

第3章 良性前列腺肥大症外科治疗市场上促进因素，阻碍因素，课题，机会

  • 推动因素，抑制，课题，机会分析

第4章 全球经济发展趋势

  • 产业趋势
    • SWOT分析
      • 优势
      • 弱点
      • 机会
      • 威胁
    • PESTEL分析
      • 政治
      • 经济
      • 社会
      • 技术
      • 环境
      • 法律
    • 价值链分析
    • 竞争销售资料分析
    • 2024年的治疗患者数(估计)
  • 潜在市场与成长潜在力分析

第5章 COVID-19影响

  • COVID-19影响
  • COVID V，U，W，L分析
  • COVID V分析
  • COVID U分析
  • COVID L分析
  • COVID-19分析

第6章 企业分析

  • BPH外科治疗市场上M&A与策略性活动分析
  • 策略性架构-全球BPH外科治疗市场
  • 业者情势-全球BPH外科治疗市场
  • 竞争环境-全球BPH外科治疗市场

第7章 摘要整理

第8章 全球良性前列腺肥大症外科治疗市场预测，2021～2034年

  • 全球良性前列腺肥大症外科治疗市场

第9章 全球良性前列腺肥大症外科治疗市场:各类型(2021～2034年)

第10章 全球良性前列腺肥大症外科治疗市场:各终端用户(2021～2034年)

第11章 全球良性前列腺肥大症外科治疗市场:各地区(2021～2034年)

第12章 北美的良性前列腺肥大症的外科治疗:各国，2021～2034年

第13章 北美的良性前列腺肥大症的外科治疗(各类型)(2021～2034年)

第14章 北美的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第15章 美国良性前列腺肥大症的外科治疗(各类型)(2021～2034年)

第16章 美国良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)(单位:100万美元)

第17章 加拿大的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第18章 加拿大的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第19章 墨西哥的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第20章 墨西哥的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第21章 欧洲的的良性前列腺肥大症的外科治疗:各国，2021～2034年

第22章 欧洲的的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第23章 欧洲的的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第24章 德国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第25章 德国的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第26章 英国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第27章 英国的良性前列腺肥大症外科治疗(各终端用户)(2021～2034年)

第28章 法国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第29章 法国的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第30章 义大利的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第31章 义大利的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第32章 西班牙的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第33章 西班牙的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第34章 瑞士的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第35章 瑞士的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第36章 荷兰的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第37章 荷兰的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第38章 其他的欧洲的良性前列腺肥大症的外科治疗各类型(2021～2034年)

第39章 其他的欧洲的良性前列腺肥大症的外科治疗(各终端用户)(2021～2034年)

第40章 亚太地区的的良性前列腺肥大症的外科治疗:各国，2021～2034年(单位:100万美元)

第41章 亚太地区的的良性前列腺肥大症的外科治疗(各类型)(2021～2034年)

第42章 亚太地区的良性前列腺肥大症外科治疗(各终端用户)(2021～2034年)

第43章 中国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第44章 中国的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第45章 日本的前列腺肥大症的外科治疗各类型趋势(2021～2034年)

第46章 日本的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第47章 印度的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第48章 印度的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第49章 韩国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第50章 韩国的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第51章 澳洲的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第52章 澳洲的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第53章 马来西亚的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第54章 马来西亚的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第55章 印尼的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第56章 印尼的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第57章 其他的亚太地区的良性前列腺肥大症的外科治疗各类型市场(2021～2034年)

第58章 其他的亚太地区的的良性前列腺肥大症的外科治疗(各终端用户)(2021～2034年)

第59章 中东·非洲的的良性前列腺肥大症的外科治疗:各国，2021～2034年(单位:100万美元)

第60章 中东·非洲的的良性前列腺肥大症的外科的治疗(各类型，2021～2034年)

第61章 中东·非洲的的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第62章 沙乌地阿拉伯的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第63章 沙乌地阿拉伯的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第64章 阿拉伯联合大公国的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第65章 阿拉伯联合大公国的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第66章 南非的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第67章 南非的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第68章 其他的中东·非洲的良性前列腺肥大症的外科的治疗(各类型)(2021～2034年)

第69章 其他的中东·非洲的良性前列腺肥大症的外科的治疗(各终端用户)(2021～2034年)

第70章 南美的良性前列腺肥大症的外科治疗:各国，2021～2034年(单位:100万美元)

第71章 南美良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第72章 南美良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第73章 巴西的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第74章 巴西的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第75章 阿根廷的良性前列腺肥大症的外科治疗(各类型，2021～2034年)

第76章 阿根廷的良性前列腺肥大症的外科治疗(各终端用户，2021～2034年)

第77章 其他的南美良性前列腺肥大症的外科的治疗(各类型)(2021～2034年)

第78章 其他的南美良性前列腺肥大症的外科治疗(各终端用户)(2021～2034年)

第79章 企业简介

  • Alembic Pharmaceuticals Limited.
  • Boston Scientific Corporation
  • Asahi Kasei Corporation
  • Coloplast Group
  • Cook Medical
  • Medifocus, Inc.
  • Karl Storz Se & Co. KG
  • Olympus Corporation
  • Medtronic
  • The Johns Hopkins Hospital
  • Cleveland Clinic

第80章 结论

第81章 参考链接

第82章 分析师的提案与推荐事项

第83章 附录

  • 调查手法
  • 调查资料来源
    • 二次资料
    • 二次资料的主要资料
    • 一次资料
    • 第一手资料的主要资料
    • 由于专业领导者的产业洞察
    • 市场预测
    • 市场预测:Top-Down(由上而下)和Bottom-Up(由下而上)的方法
    • 免责声明

第84章 调查范围

Product Code: PM5490

The benign prostatic hyperplasia surgical treatment market size is expected to reach USD 3,412.57 million by 2034, according to a new study by Polaris Market Research. The report "Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of the Prostate (TURP), Prostatic Urethral Lift], By End User, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Benign prostatic hyperplasia (BPH) surgical treatment refers to medical interventions designed to relieve urinary obstruction caused by an enlarged prostate, typically when medication fails to provide adequate relief. The growing shift toward minimally invasive surgery procedures offers faster recovery and reduced postoperative complications. There is increasing adoption of techniques that minimize tissue damage while ensuring effective symptom management as patients and healthcare providers increasingly favor less invasive options. This trend reflects a broader movement toward patient-centric care and aligns with the global focus on improving procedural outcomes and overall quality of life.

The ongoing integration of advanced surgical technologies across healthcare systems boosts growth opportunities. Innovations such as laser therapies, surgical robots, and improved visualization tools are improving the precision and efficiency of BPH surgeries. These advancements streamline operative workflows and also enable urologists to perform complex procedures with greater consistency and safety. As a result, healthcare providers are better equipped to deliver personalized treatment, reinforcing the evolution toward technologically refined and outcome-driven care models.

Benign Prostatic Hyperplasia (BPH) Surgical Treatment Market Report Highlights

In terms of type, the transurethral resection of the prostate (TURP) segment led the market in 2024, valued at USD 713.43 million, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.

Based on end user, the ambulatory surgery centers (ASCs) segment is expected to record the highest CAGR of 5.7% during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.

The North America BPH surgical treatment market accounted for the largest revenue share, and was valued at USD 888.88 million in 2024, attributed to its high BPH prevalence, rapid adoption of advanced surgical methods, and substantial healthcare spending.

Asia Pacific held a 21.61% market share in 2024, supported by rising urological health awareness and expanding investments in healthcare infrastructure.

A few global key players in the benign prostatic hyperplasia surgical treatment market include American Polyfilm, Inc.; BASF; Covestro AG; Novotex Italiana S.p.A.; RTP Company; San Fang Chemical Industry Co., Ltd.; SWM International; The Lubrizol Corporation; Toray Industries, Inc.; and Wiman Corporation.

Polaris Market Research has segmented the benign prostatic hyperplasia surgical treatment market report on the basis of type, end user, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Transurethral Resection of Prostate (TURP)

Prostatic Urethral Lift

Water Vapor Therapy

Laser Therapy

Aquablation Therapy

Transurethral Microwave Thermotherapy (TUMT)

Others

By End User Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Ambulatory Surgery Centers and Clinics

Homecare Settings

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Rationale Behind Scope Update for Benign Prostatic Hyperplasia Surgical Treatment Market

2. Global Benign Prostatic Hyperplasia Surgical Treatment Market-Report Overview

  • 2.1. Scope of the report
  • 2.2. Market Segment Analysis
  • 2.3. Regulatory Scenario by Region/Country
  • 2.4. Market Investment Scenario Strategic
  • 2.5. Market Analysis by Type (USD Million)
    • 2.5.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2024-2034)
    • 2.5.2 Transurethral Resection of the Prostate (TURP)
    • 2.5.3 Prostatic Urethral Lift
    • 2.5.4 Water Vapor Therapy
    • 2.5.5 Laser Therapy
    • 2.5.6 Aquablation Therapy
    • 2.5.7 Transurethral Microwave Thermotherapy (TUMT)
    • 2.5.8 Others
  • 2.6. Market Analysis by End User (USD Million)
    • 2.6.1 Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2024-2034)
    • 2.6.2 Hospitals
    • 2.6.3 Ambulatory Surgery Centers and Clinics
    • 2.6.4 Homecare Settings

3. driver restraint challenge and opportunities of Benign Prostatic Hyperplasia Surgical Treatment Market

  • 3.1. Driver, Restraint, Challenge and Opportunities Analysis
    • 3.1.1 Market Driver Analysis
    • 3.1.2 Market Restraint Analysis
    • 3.1.3 Market Opportunity
    • 3.1.4 Market Challenges

4. Global Growth Trends

  • 4.1. Industry Trends
    • 4.1.1 SWOT Analysis
      • 4.1.1.1 Strengths
      • 4.1.1.2 Weaknesses
      • 4.1.1.3 Opportunities
      • 4.1.1.4 Threats
    • 4.1.2 PESTEL Analysis
      • 4.1.2.1 Political Landscape
      • 4.1.2.2 Economic Landscape
      • 4.1.2.3 Social Landscape
      • 4.1.2.4 Technological Landscape
      • 4.1.2.5 Environmental Landscape
      • 4.1.2.6 Legal Landscape
    • 4.1.3 Porter's Five Forces Analysis
      • 4.1.3.1 Bargaining Power of Suppliers
      • 4.1.3.2 Bargaining Power of Buyers
      • 4.1.3.3 Threat of Substitute
      • 4.1.3.4 Threat of New Entrant
      • 4.1.3.5 Competitive Rivalry
    • 4.1.4 Value Chain Analysis
    • 4.1.5 Competitive Sales Data Analysis
    • 4.1.6 Estimated Patients Treated, 2024
  • 4.2. Potential Market and Growth Potential Analysis

5. Covid-19 Impact

  • 5.1. Covid-19 Impact
  • 5.2. COVID V, U, W and L Analysis
  • 5.3. COVID V Analysis
  • 5.4. COVID U Analysis
  • 5.5. COVID L Analysis
  • 5.6. COVID W Analysis

6. Companies Analysis

  • 6.1. M&A and Strategic Activity Analysis in BPH Surgical Treatment Market
  • 6.2. Strategy Framework - Global BPH Surgical Treatment Market
  • 6.3. Vendor Landscape - Global BPH Surgical Treatment Market
  • 6.4. Competitive Environment - Global BPH Surgical Treatment Market

7. Exceutive Summary

8. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET Forecast, 2021-2034, (USD Million)

  • 8.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market

9. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2034), (USD Million)

  • 9.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2021-2027)
  • 9.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Type (2028-2034)

10. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2034), (USD Million)

  • 10.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2021-2027)
  • 10.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by End User (2028-2034)

11. Global Benign Prostatic Hyperplasia Surgical Treatment Market by REGION (2021-2034), (USD Million)

  • 11.1. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2021-2027)
  • 11.2. Global Benign Prostatic Hyperplasia Surgical Treatment Market by Region (2028-2034)

12. North America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

  • 12.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
  • 12.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

13. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 13.1. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 13.2. North America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

14. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 14.1. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 14.2. North America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

15. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 15.1. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 15.2. United States Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

16. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 16.1. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 16.2. United States Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

17. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 17.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 17.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

18. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 18.1. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 18.2. Canada Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

19. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 19.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 19.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

20. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 20.1. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 20.2. Mexico Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

21. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2034), (USD Million)

  • 21.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
  • 21.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

22. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 22.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 22.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

23. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 23.1. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 23.2. Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

24. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 24.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 24.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

25. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 25.1. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 25.2. Germany Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

26. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 26.1. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 26.2. UK Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

27. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 27.1. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 27.2. UK Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

28. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 28.1. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 28.2. France Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

29. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 29.1. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 29.2. France Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

30. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 30.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 30.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

31. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 31.1. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 31.2. Italy Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

32. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 32.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 32.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

33. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 33.1. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 33.2. Spain Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

34. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 34.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 34.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

35. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 35.1. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 35.2. Switzerland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

36. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 36.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 36.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

37. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 37.1. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 37.2. Netherland Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

38. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 38.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 38.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

39. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 39.1. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 39.2. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

40. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

  • 40.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
  • 40.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

41. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 41.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 41.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

42. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 42.1. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 42.2. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

43. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 43.1. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 43.2. China Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

44. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 44.1. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 44.2. China Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

45. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 45.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 45.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

46. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 46.1. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 46.2. Japan Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

47. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 47.1. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 47.2. India Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

48. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 48.1. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 48.2. India Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

49. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 49.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 49.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

50. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 50.1. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 50.2. South Korea Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

51. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 51.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 51.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

52. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 52.1. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 52.2. Australia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

53. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 53.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 53.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

54. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 54.1. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 54.2. Malaysia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

55. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 55.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 55.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

56. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 56.1. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 56.2. Indonesia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

57. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 57.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 57.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

58. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 58.1. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 58.2. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

59. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

  • 59.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
  • 59.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

60. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 60.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 60.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

61. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 61.1. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 61.2. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

62. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 62.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 62.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

63. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 63.1. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 63.2. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

64. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 64.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 64.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

65. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 65.1. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 65.2. UAE Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

66. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 66.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 66.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

67. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 67.1. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 67.2. South Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

68. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 68.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 68.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

69. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 69.1. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 69.2. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

70. Latin America Benign Prostatic Hyperplasia Surgical Treatment by COUNTRIES (2021-2034), (USD Million)

  • 70.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2021-2027)
  • 70.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Countries (2028-2034)

71. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 71.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 71.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

72. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 72.1. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 72.2. Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

73. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 73.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 73.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

74. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 74.1. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 74.2. Brazil Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

75. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 75.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 75.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

76. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 76.1. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 76.2. Argentina Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

77. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2034), (USD Million)

  • 77.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2021-2027)
  • 77.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by Type (2028-2034)

78. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2034), (USD Million)

  • 78.1. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2021-2027)
  • 78.2. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment by End User (2028-2034)

79. Company Profiles

  • 79.1. Alembic Pharmaceuticals Limited.
    • 79.1.1 Company Details
    • 79.1.2 Financial (USD Million)
    • 79.1.3 Product Summary
    • 79.1.4 Recent Developments
  • 79.2. Boston Scientific Corporation
    • 79.2.1 Company Details
    • 79.2.2 Financial (USD Million)
    • 79.2.3 Product Summary
    • 79.2.4 Recent Developments
  • 79.3. Asahi Kasei Corporation
    • 79.3.1 Company Details
    • 79.3.2 Asahi Kasei Financials (USD Million)
    • 79.3.3 Product Summary
  • 79.4. Coloplast Group
    • 79.4.1 Company Details
    • 79.4.2 Financial (USD Million)
    • 79.4.3 Product Summary
  • 79.5. Cook Medical
    • 79.5.1 Company Details
    • 79.5.2 Financial (USD Million)
    • 79.5.3 Product Summary
    • 79.5.4 Recent Developments
  • 79.6. Medifocus, Inc.
    • 79.6.1 Company Details
    • 79.6.2 Financial (USD Million)
    • 79.6.3 Product Summary
    • 79.6.4 Recent Developments
  • 79.7. Karl Storz Se & Co. KG
    • 79.7.1 Company Details
    • 79.7.2 Financial (USD Million)
    • 79.7.3 Product Summary
  • 79.8. Olympus Corporation
    • 79.8.1 Company Details
    • 79.8.2 Financial (USD Million)
    • 79.8.3 Product Summary
    • 79.8.4 Recent Developments
  • 79.9. Medtronic
    • 79.9.1 Company Details
    • 79.9.2 Financial (USD Million)
    • 79.9.3 Product Summary
  • 79.10. The Johns Hopkins Hospital
    • 79.10.1 Company Details
    • 79.10.2 Financial (USD Million)
    • 79.10.3 Product Summary
    • 79.10.4 Recent Developments
  • 79.11. Cleveland Clinic
    • 79.11.1 Company Details
    • 79.11.2 Financial (USD Million)
    • 79.11.3 Product Summary
    • 79.11.4 Recent Developments

80. Conclusion

81. Reference Link

82. Analyst suggestions and recommendations

83. Appendix

  • 83.1. Methodology
  • 83.2. Research Data Source
    • 83.2.1 Secondary Data
    • 83.2.2 Key Data from Secondary
    • 83.2.3 Primary Data
    • 83.2.4 Key Data from Primary
    • 83.2.5 Industry Insight from Professional Leaders
    • 83.2.6 Market Estimation
    • 83.2.7 Market Estimation: Top-down and Bottom-up Approach
    • 83.2.8 Legal Disclaimer

84. Research Scope

LIST OF TABLES

  • TABLE 1. MARKET SEGMENT
  • TABLE 2. Global Benign Prostatic Hyperplasia Surgical Treatment Market Growth Rate by Type (USD Million) (2024-2034)
  • TABLE 3. Global Benign Prostatic Hyperplasia Surgical Treatment Market Growth Rate by End User (USD Million) (2024-2034)
  • TABLE 4. Global Benign Prostatic Hyperplasia Surgical Treatment Market - Market snapshot & key buying criteria, 2024 - 2034
  • TABLE 5. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SIZE (USD MILLION), (2021-2027)
  • TABLE 6. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD MILLION), (2028-2034)
  • TABLE 7. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 8. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 9. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 10. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 11. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Region, (2021-2027)
  • TABLE 12. Global Benign Prostatic Hyperplasia Surgical Treatment market SHARE BY Region, (2021-2027)
  • TABLE 13. Global Benign Prostatic Hyperplasia Surgical Treatment marke SIZE BY Region, (2028-2034)
  • TABLE 14. Global Benign Prostatic Hyperplasia Surgical Treatment market SHARE BY Region, (2028-2034)
  • TABLE 15. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
  • TABLE 16. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
  • TABLE 17. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 18. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 19. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 20. North America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 21. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 22. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 23. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 24. United States Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 25. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 26. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 27. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 28. Canada Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 29. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 30. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 31. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 32. Mexico Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 33. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY COUNTRIES, (2021-2027)
  • TABLE 34. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY COUNTRIES, (2028-2034)
  • TABLE 35. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 36. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 37. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 38. Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 39. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 40. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 41. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 42. Germany Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 43. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 44. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 45. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 46. UK Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 47. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 48. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 49. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 50. France Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 51. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 52. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 53. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 54. Italy Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 55. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 56. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 57. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 58. Spain Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 59. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 60. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 61. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 62. Switzerland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 63. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 64. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 65. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 66. Netherland Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 67. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 68. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 69. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 70. Rest of Europe Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 71. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
  • TABLE 72. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
  • TABLE 73. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 74. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 75. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 76. Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 77. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 78. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 79. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 80. China Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 81. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 82. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 83. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 84. Japan Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 85. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 86. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 87. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 88. India Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 89. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 90. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 91. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 92. South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 93. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 94. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 95. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 96. Australia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 97. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 98. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 99. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 100. Malaysia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 101. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 102. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 103. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 104. Indonesia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 105. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 106. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 107. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 108. Rest of Asia Pacific Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 109. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
  • TABLE 110. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
  • TABLE 111. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 112. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 113. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 114. Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 115. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 116. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 117. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 118. Saudi Arabia Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 119. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 120. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 121. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 122. UAE Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 123. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 124. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 125. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 126. South Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 127. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 128. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 129. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 130. Rest of Middle East & Africa Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 131. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2021-2027)
  • TABLE 132. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY Countries, (2028-2034)
  • TABLE 133. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 134. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 135. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 136. Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 137. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 138. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 139. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 140. Brazil Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 141. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 142. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 143. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 144. Argentina Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)
  • TABLE 145. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2021-2027)
  • TABLE 146. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY TYPE, (2028-2034)
  • TABLE 147. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2021-2027)
  • TABLE 148. Rest of Latin America Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million) BY END USER, (2028-2034)

LIST OF FIGURES

  • FIGURE 1. Market Overview
  • FIGURE 2. DROC of Benign Prostatic Hyperplasia Surgical Treatment Analysis
  • FIGURE 3. SWOT Analysis
  • FIGURE 4. PESTEL Analysis
  • FIGURE 5. Porter's Five Forces Analysis
  • FIGURE 6. Value Chain Analysis
  • FIGURE 7. COVID V, U, W and L Analysis
  • FIGURE 8. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2021-2027), (USD MILLION)
  • FIGURE 9. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD MILLION), (2028-2034)
  • FIGURE 10. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2021-2027), (USD MILLION), by Region
  • FIGURE 11. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SHARE, (2027), by Region
  • FIGURE 12. Global Benign Prostatic Hyperplasia Surgical Treatment Market Size (USD Million), (2028-2034), (USD MILLION), by Region
  • FIGURE 13. Global Benign Prostatic Hyperplasia Surgical Treatment MARKET SHARE, (2034), by Region